OLUWATOSIN OLUNUGA

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health SUCCASUNNA, NJ NPI 1467723601

General Payments — all program years on this page

$1,046.48

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 39
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $475.73 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $475.7320

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $367.7013
Janssen Pharmaceuticals, Inc $60.004
Axsome Therapeutics, Inc. $33.302
Supernus Pharmaceuticals, Inc. $14.731

By program year

Program yearAmountRecords
2022 $107.304
2023 $463.4515
2024 $475.7320

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078095748 Janssen Pharmaceuticals, Inc $15.00 03/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078095750 Janssen Pharmaceuticals, Inc $15.00 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078095754 Janssen Pharmaceuticals, Inc $15.00 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078095756 Janssen Pharmaceuticals, Inc $15.00 04/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763722 ABBVIE INC. $8.85 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763724 ABBVIE INC. $10.04 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763726 ABBVIE INC. $124.62 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763728 ABBVIE INC. $8.75 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763730 ABBVIE INC. $8.74 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763732 ABBVIE INC. $7.36 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763734 ABBVIE INC. $18.00 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763736 ABBVIE INC. $4.81 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763738 ABBVIE INC. $18.00 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763740 ABBVIE INC. $11.60 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763742 ABBVIE INC. $11.83 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763744 ABBVIE INC. $12.27 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107763746 ABBVIE INC. $122.83 12/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147881126 Supernus Pharmaceuticals, Inc. $14.73 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148398869 Axsome Therapeutics, Inc. $15.45 05/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148398871 Axsome Therapeutics, Inc. $17.85 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.